We have previously demonstrated in a separate cohort of relapsed MCL patients that the 30% (9/30) of patients with p4E-BP1+ tumors had a shorter progression-free survival when treated with the mTORC1 inhibitor temsirolimus and rituximab.[21]. Here, EIF4EBP1 is linked to mantle cell lymphoma.